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Background: Rift Valley Fever (RVF) is a viral zoonosis that historically affects livestock production and human health in
sub-Saharan Africa, though epizootics have also occurred in the Arabian Peninsula. Whilst an effective live-attenuated
vaccine is available for livestock, there is currently no licensed human RVF vaccine. Replication-deficient chimpanzee
adenovirus (ChAd) vectors are an ideal platform for development of a human RVF vaccine, given the low prevalence of
neutralizing antibodies against them in the human population, and their excellent safety and immunogenicity profile in
human clinical trials of vaccines against a wide range of pathogens.
Methods: Here, in BALB/c mice, we evaluated the immunogenicity and efficacy of a replication-deficient chimpanzee
adenovirus vector, ChAdOx1, encoding the RVF virus envelope glycoproteins, Gn and Gc, which are targets of virus
neutralizing antibodies. The ChAdOx1-GnGc vaccine was assessed in comparison to a replication-deficient human
adenovirus type 5 vector encoding Gn and Gc (HAdV5-GnGc), a strategy previously shown to confer protective
immunity against RVF in mice.
Results: A single immunization with either of the vaccines conferred protection against RVF virus challenge eight
weeks post-immunization. Both vaccines elicited RVF virus neutralizing antibody and a robust CD8+ T cell response.
Conclusions: Together the results support further development of RVF vaccines based on replication-deficient
adenovirus vectors, with ChAdOx1-GnGc being a potential candidate for use in future human clinical trials.
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Rift valley fever (RVF) is one of numerous zoonotic dis-
eases affecting human and livestock health in Africa, and
has previously spread to the Arabian Peninsula [1,2]. The
disease is caused by a mosquito-borne, negative-stranded
RNA virus of the Bunyaviridae family, RVF virus, that was
first isolated in 1930 from sheep on a Kenyan farm [3].
RVF virus can infect a wide range of domestic and wild
animals, but pathology is most severe in sheep where al-
most 100% mortality and abortion rates occur in newborn
lambs and pregnant ewes, respectively [3]. In humans,
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stated.animal tissue or body fluids and presents as a mild febrile
illness that sometimes progresses to more severe, fatal
manifestations such as encephalitis and hemorrhage. Al-
though a highly effective live-attenuated vaccine known as
Clone 13 [4] is available for livestock use in RVF-endemic
countries, no licensed livestock vaccines are available for
use in RVF-free areas such as Europe and there is cur-
rently no licensed human RVF vaccine.
Humans and animals recovering from infection with
RVF virus develop long-lasting immunity that is attribut-
able to the acquisition of virus-neutralizing antibodies
[3,5-8]. These virus-neutralizing antibodies mainly target
the Gn and Gc envelope glycoproteins (of which there is
only one serotype) encoded in the M segment of the RVF
virus genome [9-11]. Subunit vaccines incorporating oneral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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sponse that may confer complete protection from experi-
mental RVF viral challenge in rodents and livestock
(reviewed in [12]). Thus, development of Gn and Gc-based
vaccines utilizing vectors with an established human safety
profile could be a promising strategy for a future human
RVF vaccine.
Replication-deficient adenovirus vectors have so far been
used in human clinical trials of vaccines against Plasmo-
dium falciparum [13], human immunodeficiency virus
[14], Mycobacterium tuberculosis [15], hepatitis C virus
[16] and influenza virus [17] in many thousands of adults,
children and infants in Europe and Africa, including coun-
tries that are prone to frequent RVF epizootics. These
studies have highlighted the excellent safety and immuno-
genicity profile of adenovirus vectors in humans, with simi-
lar properties observed in several animal species (including
those susceptible to RVF) where adenovirus-vectored vac-
cines have been tested against multiple diseases [18-27].
Development of an effective adenovirus-vectored RVF vac-
cine may therefore provide a prophylactic tool that could
be used not only in humans, but also in the animal species
susceptible to RVF.
To this end, we evaluated the immunogenicity and effi-
cacy of a replication-deficient chimpanzee adenovirus vec-
tor, ChAdOx1 [28], encoding the RVF virus glycoproteins
Gn and Gc (ChAdOx1-GnGc) in BALB/c mice. The ChA-
dOx1 vector, unlike the widely tested human adenovirus
type 5 (HAdV5) vector, is not affected by significant pre-
existing anti-vector immunity that may limit vaccine per-
formance in the human population [28]. Though ChAdOx1
is phylogenetically classified as a Human adenovirus E, its
serotype is distinct from HAdV5 (a Human adenovirus C)
[28-30], meaning that anti-vector immunity to HAdV5 can-
not dampen the potency of a ChAdOx1-vectored vaccine.
Furthermore, ChAdOx1 is currently in clinical develop-
ment for human influenza and tuberculosis vaccines, mak-
ing it a good candidate vector for a human RVF vaccine.
We therefore assessed the immunogenicity and effi-
cacy of the ChAdOx1-GnGc vaccine in comparison with
a HAdV5 vector encoding Gn and Gc (HAdV5-GnGc),
a strategy previously shown to induce protective immun-
ity against RVF in mice [31]. In addition, we examined
the effect of two commercially available adjuvants,
Matrix-M™ and AddaVax™, on the RVF virus neutralizing
antibody response elicited by the ChAdOx1-GnGc and
HAdV5-GnGc vaccines. Matrix-M™ is a saponin-based
adjuvant developed for human use [32], whereas AddaVax™
is a squalene-based oil-in-water emulsion whose formula-
tion is similar to the MF59® adjuvant licensed for human
influenza vaccines [33]. Both these adjuvants were selected
for use in this study based on their ability to enhance
antibody responses induced by candidate human influenza
vaccines [32,34-36].Results
Induction of RVF virus neutralizing antibodies and
efficacy against RVF virus challenge
We first compared RVF virus neutralizing antibody titers
between vaccination regimens, measured in sera sampled
eight weeks post-vaccination. As shown in Figure 1 both
vaccines elicited RVF virus neutralizing antibodies, though,
in the absence of adjuvants, mice receiving HAdV5-GnGc
mounted higher virus neutralizing titers than those vacci-
nated with ChAdOx1-GnGc (Mann–Whitney U test p =
0.004; Figure 1). However, this difference in immunogen-
icity was no longer evident when comparisons were made
between the HAdV5-GnGc group and the groups receiving
ChAdOx1-GnGc in co-administration with either Matrix-
M™ or AddaVax™ adjuvant (Kruskal-Wallis test p = 0.6).
Both Matrix-M™ and AddaVax™ adjuvant significantly
enhanced the RVF virus neutralizing response induced by
ChAdOx1-GnGc, but the slight increase in HAdV5-GnGc
immunogenicity by either adjuvant did not reach statistical
significance (Figure 1). Nevertheless, all ChAdOx1-GnGc
and HAdV5-GnGc vaccination regimens conferred pro-
tection from clinical disease and mortality following chal-
lenge with a lethal dose of the South African 56/74 RVF
virus strain (Table 1). In contrast all unvaccinated controls
developed clinical illness following RVF viral challenge,
with five of six mice succumbing to the infection.
Induction of cellular immune responses by ChAdOx1-GnGc
and HAdV5-GnGc vaccines
We next evaluated vaccine-induced T cell responses using
overlapping 15mer peptides (N = 265) generated from the
Gn and Gc glycoproteins of the MP-12 RVF virus strain.
First, the peptides were screened for their ability to re-
stimulate interferon gamma (IFNγ) production by spleno-
cytes obtained from mice vaccinated with HAdV5-GnGc
as measured by enzyme-linked immunospot assay (ELI-
Spot). In this pilot study, fourteen of the 265 peptides were
found to re-stimulate IFNγ ELISpot responses >100 spot
forming cells (SFC)/million splenocytes (range, 125 to
1600 SFC/ million splenocytes) (Figure 2A). Responses to
all other peptides were below this arbitrary threshold.
As shown in Figure 2 several of the fourteen peptides
elicited CD8+ T cell responses as measured by intracellu-
lar cytokine staining assay, but CD4+ T cells were barely
detectable (Figure 2B-D). Next, a pool of these fourteen
peptides, eleven of which encompassed predicted major
histocompatibility (MHC) class-I epitopes (Additional file 1:
Table S1), was made and used to assess T-cell responses
elicited by the ChAdOx1-GnGc and HAdV5-GnGc vaccin-
ation regimens.
The frequency of IFNγ spot-forming splenocytes mea-
sured by ELISpot was higher among mice receiving
HAdV5-GnGc than in those receiving ChAdOx1-GnGc
when compared at two weeks (Mann–Whitney U test
Figure 1 Induction of virus neutralizing antibodies by ChAdOx1-GnGc and HAdV5-GnGc vaccines. For each vaccination regimen the virus
neutralizing response (VNT50), acquired as the antibody titer resulting in 50% reduction of plaque formation relative to cells incubated with RVF
virus in the absence of mouse serum, is shown. The data represent medians (bars) and interquartile ranges (error bars) for 14 mice per regimen.
The Mann–Whitney U test is used for statistical comparisons between regimens. ** p <0.01, NS – not significant.
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(Mann–Whitney U test p = 0.003; Additional file 1:
Figure S3). Neither Matrix-M™ nor AddaVax™ signifi-
cantly enhanced the IFNγ ELISpot responses induced by
ChAdOx1-GnGc and HAdV5-GnGc though responses in
the HAdV5 plus AddaVax™ regimen were notably higher
(Figure 3A and Additional file 1: Figure S3).
Intracellular cytokine staining assay of peripheral
blood mononuclear cells (PBMCs) sampled two weeks
post-vaccination revealed a robust CD8+ T cell responseTable 1 Efficacy of ChAdOx1-GnGc and HAdV5-GnGc vac-








ChAdOx1-GnGc + 25μl AddaVax™ 0/6 0
ChAdOx1-GnGc + 25μg Matrix-M™ 0/6 0
HAdV5-GnGc 0/6 0
HAdV5-GnGc + 25μl AddaVax™ 0/6 0
HAdV5-GnGc + 25μg Matrix-M™ 0/6 0
Unvaccinated controls 6/6 21380
For each vaccination regimen the number of mice developing clinical signs of
RVF following challenge with RVF virus is shown. Viraemia, assessed by RVF
virus isolation three days post-challenge, is presented as median TCID50/ml for
each regimen.mainly comprising cells staining positive for IFNγ or
tumor necrosis factor alpha (TNFα) or both these cyto-
kines and very infrequent interleukin 2 positive (IL-2+)
cells (Figure 3B-E and Additional file 1: Figure S2). The
HAdV5 plus AddaVax™ regimen had the highest frequen-
cies of any of the three CD8+ T cell subsets (Figure 3B-D).
The predominance of IFNγ and TNFα in the CD8+ T
cell response was a feature of all vaccination regimens
(Figure 3E) and has previously been observed following
adenoviral-vectored vaccination of BALB/c mice with
recombinant malaria parasite antigens [37].
Discussion
Adenovirus vectors are ideal for use in vaccines against
zoonotic diseases such as RVF, as they have the potential to
be deployed in humans and in a wide range of animal spe-
cies. Replication-deficient chimpanzee adenovirus vectors
such as ChAdOx1 are particularly attractive for this pur-
pose given the low prevalence of neutralizing antibodies
against them in the human population [28,29,38,39], but
they have previously not been utilized for a RVF vaccine.
Here, we have shown that a single immunization with the
ChAdOx1-GnGc vaccine confers protection against RVF
viral challenge in mice, supporting its further development
for use in future human clinical trials and in susceptible
animal species. We also confirm previous observations on
the induction of protective immunity by HAdV5-vectored
Figure 2 Cellular responses to overlapping peptides from the Gn and Gc glycoproteins of RVF virus. Presented is the median (bars) and
range (error bars) of number of cells producing IFNγ in an ELISpot assay following restimulation of pooled splenocytes for 18 hours with each of
265 overlapping peptides (each at a final concentration of 5 μg/ml) spanning the entire Gn and Gc glycoprotein from MP-12 RVF virus strain (A).
The splenocytes were obtained two weeks post-vaccination with HAdV5-GnGc (N = 5) or HAdV5 lacking a transgenic open reading frame, HAdV5-Empty
(N = 5). Only responses exceeding an arbitrary cut-off of >100 SFC/million splenocytes are shown. Responses to all other peptides were below this arbitrary
threshold. Numbers in parentheses represent the peptide identification number, with peptides 7, 18, 19, 22, 23 and 62 contained in the Gn glycoprotein
and the rest in the Gc glycoprotein. The median frequencies and range of CD8+ and CD4+ T cells staining positive for IFNγ (B), TNFα (C) or IL-2 (D) as
measured by ICS on splenocytes is also shown.
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prevalence of neutralizing antibodies against the HAdV5
vector in humans may limit vaccine performance [29,40],
the HAdV5-GnGc vaccine could still be used in animals.
Indeed, a HAdV5-based vaccine against foot-and-mouth
disease has recently been licensed for livestock use in the
United States of America [41].RVF virus neutralizing antibodies have been shown to
be sufficient for protection against RVF [12,42] but T
cells might also be expected to play a role in immunity
through clearance of virus-infected cells. To this end T
cell depletion studies have recently found that CD4+ T cells,
but not CD8+ T cells, can influence development of
immunity against RVF neuropathology in the C56BL/6
Figure 3 (See legend on next page.)
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Figure 3 Induction of T cell responses by ChAdOx1-GnGc and HAdV5-GnGc vaccines. Presented is a summary of the T cell response elicited
by each vaccination regimen as measured by ELISpot assay on splenocytes (A; N = 6 mice per regimen) or intracellular cytokine staining of PBMCs
(B to E; N = 14 mice per regimen) two weeks post-vaccination. The bars represent medians and error bars, the interquartile ranges. The Mann–Whitney
U test is used for statistical comparisons between regimens. The pie charts in E represent the relative contribution of CD8+ T cells staining positive for
one cytokine (yellow pie slices), two cytokines (green pie slices) or all three cytokines (red pie slices) to the responses shown in panels B to D. The raw
frequencies of the different CD8+ T cell phenotypes are presented in Additional file 1: Figure S2. ** p <0.01, NS – not significant.
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virus [43]. However, the relative role of different T cell phe-
notypes in the BALB/c mouse model remains unknown.
Here, we find that ChAdOx1-GnGc and HAdV5-GnGc
vaccines can readily induce an RVF virus glycoprotein-
specific CD8+ T cell response in BALB/c mice, as has been
observed in a recent study using DNA and modified vac-
cinia virus Ankara-vectored Gn-Gc vaccines [44]. The ro-
bust immunogenicity of both ChAdOx1-GnGc and
HAdV5-GnGc for RVF virus neutralizing antibodies and
for CD8+ T cells presents an opportunity for dissecting the
relative contribution of CD8+ T cells to protective immun-
ity against RVF in the BALB/c mouse model.
Finally we sought to assess whether two commercially
available adjuvants, Matrix-M™ and AddaVax™, could en-
hance the immunogenicity of ChAdOx1-GnGc and
HAdV5-GnGc, with the aim of selecting a vaccine plus
adjuvant regimen for evaluation of a vaccine dose-sparing
effect in future trials in livestock. Both adjuvants improved
the RVF virus neutralizing antibody response induced by
ChAdOx1-GnGc, but not HAdV5-GnGc. However, nei-
ther significantly enhanced the vaccine-induced T cell re-
sponse to ChAdOx1-GnGc but co-administration of
HAdV5-GnGc with AddaVax™ resulted in an increase in
the frequency of CD8+ IFNγ+ and CD8+ TNFα+ T
cells. These findings may suggest that Matrix-M™ and
AddaVax™ could be generally useful for antibody induction
by other chimpanzee adenovirus-vectored vaccines, and
AddaVax™ for T cell induction by HAdV5-vectored
vaccines, but this requires further study. The greatest
enhancement in ChAdOx1-GnGc-induced virus neu-
tralizing antibody titers was with Matrix-M™ adjuvant,
which is licensed for both human and animal use. Future
studies in livestock will be invaluable in determining
whether Matrix-M™ adjuvant enhances the magnitude
and longevity of the RVF virus neutralizing antibody
response induced by ChAdOx1-GnGc, ultimately inform-
ing the design of subsequent human clinical trials of
ChAdOx1-GnGc.
Conclusions
In summary our data highlight the potential utility of
ChAdOx1 and HAdV5 vectors in vaccines against RVF
and provide evidence in support of ChAdOx1-GnGc as a
potential candidate for the much-needed human RVF vac-
cine. Further, both ChAdOx1-GnGc and HAdV5-GnGchold promise as livestock vaccines and, like most sub-
unit RVF vaccines in development [12], allow differenti-
ation of infected versus vaccinated animals (DIVA)
using commercially available DIVA tests that detect im-
mune responses to RVF virus components other than
Gn and Gc. Nevertheless, a better idea of the potency of
the ChAdOx1-GnGc and HAdV5-GnGc vaccines will
only emerge from further studies in target species such
as sheep, goats and cattle.
Methods
Generation of replication-deficient adenovirus vectored
RVF vaccines
The ChAdOx1-GnGc and HAdV5-GnGc genomic clones
were prepared by Gateway® recombination (Life Technolo-
gies Ltd, UK) between an entry plasmid containing the M
segment of the MP-12 RVF virus strain [45], starting from
the fourth initiation codon (Genbank accession number
DQ380208, bases 411–3614), and an E1- and E3-deleted
ChAdOx1 destination plasmid [28] or the E1-and E3-
deleted human adenovirus type 5 destination plasmid
pAd/PL-DEST™ (Life Technologies Ltd, UK, here termed
HAdV5). After viral rescue and propagation in human
embryonic kidney 293 cells [46], the resulting replication-
deficient ChAdOx1-GnGc and HAdV5-GnGc viruses
were purified by CsCl gradient ultracentrifugation.
Both vectors encoded the 1,067 amino acid Gn and Gc
RVF viral polyprotein under the control of the human cyto-
megalovirus major immediate early promoter (Additional
file 1: Figure S1). The N terminus of the Gn-Gc polyprotein
contained an in-frame fusion of the human tissue plas-
minogen activator leader sequence, known to enhance
transgene expression and immunogenicity [47]. The C
terminus of the polyprotein contained a H-2Kd restricted
CD8+ T cell epitope SYIPSAEKI from Plasmodium berghei
circumsporozoite protein (Pb9) [48] and an anti-V5 mono-
clonal antibody recognition sequence IPNPLLGLD.
Western blotting confirmed expression of the respective
antigens with the predicted molecular weight by both
vectors (Additional file 1: Figure S1).
Immunizations and RVF virus challenge
For each vaccination regimen, a total of 20 female BALB/c
(H-2d) mice (Harlan, UK) aged 6–8 weeks old were immu-
nized with 1 × 108 infectious units of the respective vector
in phosphate-buffered saline (PBS). These were either
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juvants, AddaVax™ (InvivoGen, USA, used at 25 μl per
mouse) and Matrix-M™ (Isconova, Sweden, used at 25 μg
per mouse). All immunizations were intramuscular and
were performed under isofluorane anesthesia in a total
volume of 50 μl administered to the right posterior tibi-
alis muscle.
Six vaccination regimens were evaluated in this study: i)
ChAdOx1-GnGc without adjuvant, ii) ChAdOx1-GnGc plus
Matrix-M™ adjuvant, iii) ChAdOx1-GnGc plus AddaVax™
adjuvant, iv) HAdV5-GnGc without adjuvant, v) HAdV5-
GnGc plus Matrix-M™ adjuvant and vi) HAdV5-GnGc plus
AddaVax™ adjuvant.
Sampling for immunological assays was done as follows.
Two weeks post-vaccination, blood samples were taken
from eight mice per regimen for intracellular cytokine
staining (ICS) assays on peripheral blood mononuclear
cells (PBMCs) as described [49]. A further six mice were
culled at this time point and spleens and blood were har-
vested for interferon gamma (IFNγ) enzyme-linked immu-
nospot assay (ELISpot) on splenocytes [50] and ICS assays
on PBMCs, respectively. Eight weeks post-vaccination,
blood samples were taken from all remaining mice (14 per
regimen) and eight mice culled per regimen for IFNγ ELI-
Spot on splenocytes. After another 48 hours the remaining
mice (6 mice per regimen), together with an additional
group of six unvaccinated BALB/c mice, were all chal-
lenged with 1 × 103 plaque-forming units (pfu) of the
South African RVF virus strain 56/74 via the intraperito-
neal route as described [44].
The primary endpoint for efficacy estimation was the
development of clinical signs of illness including ruffled
fur, hunched posture and reduced activity, as described
[51], and this was monitored daily over 21 days. We also
assessed viraemia and mortality post-challenge as second-
ary endpoints. For assessment of peak viraemia ~50 μl of
blood was sampled at days 3 and 6 post-challenge and
used for virus isolation. All surviving mice were culled
after 21 days of follow-up.
All animal procedures were conducted in accordance
with the United Kingdom Animals (Scientific Procedures)
Act Project Licence (PPL30/2889) and were approved by
the University of Oxford Animal Care and Ethical Review
Committee and the Centro de Investigación en Sanidad
Animal, Instituto Nacional de Investigación Agraria y
Alimentaria (CISA-INIA) Committees on Biosafety and
Ethics of Animal Experimentation (permits CBS2012/017
and CEEA2012/14) in accordance with regulatory guide-
lines from the European Community Council Directive
86/609/EEC.
Assessment of RVF virus neutralizing antibodies
The titer of vaccine-induced RVF virus-neutralizing anti-
bodies was measured as previously described [44]. Briefly,sera were first heat-inactivated at 56°C for 30 minutes and
two-fold serial dilutions of each made in Dulbecco’s Modi-
fied Eagle Medium (DMEM) containing 2% fetal bovine
serum. Fifty microliters of each diluted serum was mixed
with an equal volume of medium containing 1200 pfu of
the MP-12 RVF virus strain and incubated for 1 hour at
37°C. This serum-virus mixture was then transferred
onto 96-well plates containing Vero cell monolayers
and incubated at 37°C in the presence of 5% CO2. After
72 hours the cells were fixed and stained in a solution
containing 10% formaldehyde and 2% crystal violet in
PBS. Plaque formation was then scored and neutralization
titer defined as the highest serum dilution at which plaque
formation was reduced by 50% relative to that in cells in-
cubated with MP-12 RVF virus only. The assays were per-
formed in triplicate and scored by an operator blinded to
vaccination regimen.
Assessment of T cell responses to RVF viral glycoproteins
RVF viral glycoprotein-specific T cells were measured by
IFNγ ELISpot assay on splenocytes [50] and ICS on
PBMCs [49]. Our strategy involved: 1) pre-screening of
265 overlapping 15mer peptides (overlapping by 11 amino
acids) spanning the Gn and Gc glycoproteins from the
MP-12 RVF virus by IFNγ ELISpot on splenocytes from
mice vaccinated with HAdV5-GnGc, 2) preparation of a
peptide pool composed of peptides found to re-stimulate
>100 spot-forming cells (SFC)/million splenocytes, and 3)
use of the peptide pool for IFNγ ELISpot and ICS assays
on splenocytes and PBMCs from mice vaccinated with the
ChAdOx1-GnGc and HAdV5-GnGc regimens considered
here. The peptides were synthesized in a PepSet™ format
(Mimotopes, UK) to ~70% purity using the Gn and Gc se-
quence from the MP-12 RVF virus strain (Genbank acces-
sion number DQ380208, bases 411–3614). The stock
peptides were reconstituted in 100% dimethyl sulfoxide
and cell culture media (DMEM containing 10% fetal calf
serum) used to further dilute each peptide for use at a final
concentration of 5 μg/ml in all assays. For IFNγ ELISpot
assays peptide re-stimulation of splenocytes was done for
18 hours [50]. For ICS assays, peptide re-stimulation of
PBMCs was done for 5 hours and the frequency of cells
staining positive for IFNγ, tumor necrosis factor alpha
(TNFα) or interleukin 2 (IL-2) measured by flow cytome-
try as described [49].
Statistical analysis
All analyses were performed using GraphPad PRISM®
version 5.0 with alpha = 0.05. For each vaccine, the
Mann–Whitney U test was used to assess the effect of
co-administration with either Matrix-M™ or AddaVax™
adjuvant on the induced antibody and T cell response.
The Kruskal-Wallis test was used for univariate com-
parisons involving more than two regimens.
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Additional file 1: Figure S1. Vaccine design and confirmation of
transgene expression. Figure S2. Cytokine profiling of vaccine-induced
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vaccination. Table S1. Software prediction of epitopes within immunodo-
minant peptides.
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